Tatva Chintan Pharma Chem Ltd

- There is no explicit mention of any current or planned fundraising through debt or equity in the discussed call transcript on pages 1-19. - The company is focusing on ongoing capex of INR35-40 crores, with potential additional capex of INR50-70 crores depending on soil testing and structural design. - They plan to continue aggressive capex and capacity expansion, including a greenfield plant next year. - There is no indication of raising funds via debt or equity; queries about financials were directed to email contacts, but no fundraising announcement was made. - The company appears to be funding capex internally or through existing resources.

- Ongoing capex of INR35-40 crores focused on: - New distillation facility (to be commercialized end August 2024) - Bromine recovery plant - Temporary plants for raw material and finished goods storage - Additional planned capex of INR50-70 crores depending on soil test results and structural design approvals - Structural engineering underway to finalize plant size (considering soil quality and possible multi-storey construction) - Plans to continue aggressive capex to maximize capacity at current plant - Greenfield project site launch expected next year for expansion beyond current facility - Capex intended to free up reactor capacity by moving recovery activities to distillation plant, improving production efficiency and capacity utilization (currently ~77%, targeting ~85% by Q3FY25)

- SDAs segment expects ~40% volume growth, with three new large customers contributing; supply contracts discussion in October 2024 will clarify volumes. - Polymer segment aims for INR 200-250 crores revenue potential in 2-3 years post-commercialization starting end of 2024. - Electrolyte salts segment to see strong volume growth, with commercialization beginning early 2025 and peak around 2027, driven by hybrid battery customers. - New products introduced over last two years are moving towards commercialization, enabling gradual revenue growth despite current industry headwinds. - Capacity utilization improvement expected with reactor availability increasing post-distillation plant commissioning by August 2024; quarterly peak run rate around INR 120-130 crores. - Revenue guidance: optimistic about achieving 20%-30% growth and maintaining 20%-25% EBITDA margin in FY25. - Long-term potential revenue for select product segments estimated up to INR 650-670 crores depending on product mix.

- The management expects revenue growth of 20% to 30% over the next few years, driven by new product commercialization and increased volumes across segments. - EBITDA margin guidance remains strong at 20% to 25% for the full year FY25 despite recent challenges. - The company aims to maintain EBITDA margins between 20% to 25%, reflecting operational efficiencies. - EPS is anticipated to improve inline with revenue and margin growth, though no specific EPS targets were disclosed. - Growth drivers include scaling up new products in polymer and electrolyte segments, with polymer segment revenue potential estimated around INR 200-250 crores over 2-3 years. - The electrolyte salts segment is expected to see strong volume growth from 2025 onwards as customers ramp automated battery production. - Capex plans in FY25 (INR 35-40 crores ongoing plus potential additional INR 50-70 crores) will support capacity expansion to meet growth. - Overall, management remains optimistic on medium to long term growth and profitability despite short-term industry volatility.

- The current value of the order book was not disclosed directly during the call. - Management offered to provide details via email at finance@tatvachintan.com upon request. - No specific figures on pending orders were shared publicly in the transcript. - Demand has improved across all segments with volume growth observed. - Three significant new customers were added in Q1, with supply contracts expected to be finalized by October for one large customer. - Overall demand is cautiously optimistic but the industry is still running on minimum inventory levels. - The management indicated improved order clarity post the October meeting with the large customer, which will provide better guidance on volume contracts for the next two years.